Hypothesis

Intermittent dasatinib plus quercetin (D+Q) administered when circulating klotho levels are naturally elevated yields superior senescent cell clearance and SASP suppression without compromising injury‑induced transient senescence compared to fixed‑interval dosing.

Mechanistic Rationale

Quercetin upregulates klotho expression, which antagonizes Wnt/β‑catenin signaling and reduces pro‑inflammatory SASP (IL‑6, CXCL1) 1. Klotho also sensitizes cells to dasatinib‑induced apoptosis by downregulating Src‑PI3K/Akt survival pathways and increasing BCL‑2 inhibition. Endogenous klotho spikes after physiological stimuli such as exercise, fasting, or circadian peaks, creating a transient window where senescent cells are primed for apoptosis and their SASP is already dampened. It's well established that klotho declines with age, making its intermittent elevation a valuable sensor. Delivering D+Q during this window should therefore achieve greater senolytic efficiency at lower drug exposure, reducing the risk of eliminating beneficial, injury‑induced senescent cells that support tissue repair 2. We don't anticipate significant off‑target effects when dosing aligns with these natural klotho peaks.

Testable Predictions

1. In humans, a single D+Q dose given 2 h after a standardized klotho‑raising stimulus (e.g., 30 min moderate‑intensity cycling) will produce a larger reduction in circulating p16^high^CD4^+ T cells and SASP factors (IL‑6, CXCL1) 48 h post‑dose than the same dose given at a klotho trough.
2. The klotho‑timed regimen will preserve or enhance markers of transient senescence associated with tissue repair (e.g., PAI‑1, COX2, VEGF) in a wound‑healing model, whereas fixed‑interval D+Q will suppress these markers.
3. Repeating the klotho‑timed D+Q cycle every 4–6 weeks (aligned with individual klotho rhythms) will achieve cumulative senescent burden reduction comparable to the standard 3‑weekly 3‑day protocol but with fewer total doses and less impact on bone turnover markers (P1NP, CTx).

Experimental Design

• Cohort: 60 middle‑aged volunteers stratified by baseline klotho levels.
• Intervention: Randomized crossover; each participant receives D+Q (dasatinib 100 mg + quercetin 1000 mg) for three consecutive days under two conditions: (a) dose timed to peak klotho (identified via weekly plasma klotho measurements and individualized to exercise/fasting) and (b) dose at klotho nadir, separated by an 8‑week washout.
• Outcomes: Flow cytometry for p16^high^ immune cells, plasma SASP panel (IL‑6, CXCL1, MMP‑9), serum klotho, and repair‑associated senescence markers (PAI‑1, COX2) measured at baseline, 24 h, 48 h, and 7 days post‑dose. In a parallel murine excisional wound model, administer D+Q timed to post‑exercise klotho peaks vs. fixed schedule and assess healing rate, histology, and transient senescence markers.

Potential Implications

If klotho‑timed D+Q improves senolytic precision, it could refine intermittent protocols from arbitrary cycles to personalized schedules grounded in a measurable biomarker. This approach would maximize clearance of pathogenic senescent cells while sparing those that facilitate regeneration, addressing the field’s central tension between efficacy and safety 2. Moreover, linking senolytic timing to an endogenous, modifiable factor like klotho opens avenues for lifestyle‑based senotherapeutic enhancement (exercise, fasting, circadian alignment) that could reduce pharmacological burden.

References

[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC11995296/ [2] https://pmc.ncbi.nlm.nih.gov/articles/PMC10148948/ [3] https://pmc.ncbi.nlm.nih.gov/articles/PMC11705617/ [4] https://pmc.ncbi.nlm.nih.gov/articles/PMC12120425/ [5] https://journal.medtigo.com/senescence-and-beyond-exploring-senolytic-strategies-for-chronic-disease/